Eli Lilly Hit With $90M Verdict In Nektar's Rezpeg Breach Suit
By Bonnie Eslinger ( September 24, 2026, 7:33 PM EDT) -- A California federal jury on Thursday found Eli Lilly breached the implied covenant of good faith and fair dealing in an agreement to co-develop Nektar Therapeutics' autoimmune-disease drug Rezpeg, awarding Nektar $90 million — a considerable sum that fell short of the $1 billion the clinical-stage biotech company had sought....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.